Member Exclusive

ISCT revises cell and gene therapy forecast following FDA approval of Novartis CAR-T therapy

Following FDA approval of the Novartis CAR-T cell therapy CTL019, ISCT forecasts significant investment and funding throughout entire cell and gene therapy sector.

Go to the profile of Freya Leask
Aug 31, 2017

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.


No comments yet.